These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 22038899

  • 1. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.
    Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, Picard O, Chowers Y, Eliakim R, Ben-Horin S.
    Inflamm Bowel Dis; 2012 Sep; 18(9):1628-33. PubMed ID: 22038899
    [Abstract] [Full Text] [Related]

  • 2. Significance of low level infliximab in the absence of anti-infliximab antibodies.
    Ungar B, Anafy A, Yanai H, Ron Y, Yavzori M, Picard O, Fudim E, Loebstein R, Kopylov U, Chowers Y, Dotan I, Eliakim R, Ben-Horin S.
    World J Gastroenterol; 2015 Feb 14; 21(6):1907-14. PubMed ID: 25684959
    [Abstract] [Full Text] [Related]

  • 3. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
    Van Stappen T, Billiet T, Vande Casteele N, Compernolle G, Brouwers E, Vermeire S, Gils A.
    Inflamm Bowel Dis; 2015 Sep 14; 21(9):2172-7. PubMed ID: 26284296
    [Abstract] [Full Text] [Related]

  • 4. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
    Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, van den Brink GR, DʼHaens GR.
    Inflamm Bowel Dis; 2017 Apr 14; 23(4):650-660. PubMed ID: 28195852
    [Abstract] [Full Text] [Related]

  • 5. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
    Nanda KS, Cheifetz AS, Moss AC.
    Am J Gastroenterol; 2013 Jan 14; 108(1):40-7; quiz 48. PubMed ID: 23147525
    [Abstract] [Full Text] [Related]

  • 6. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
    Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, Lockton S, Ling N, Singh S.
    J Immunol Methods; 2012 Aug 31; 382(1-2):177-88. PubMed ID: 22691619
    [Abstract] [Full Text] [Related]

  • 7. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
    Pallagi-Kunstár É, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T.
    World J Gastroenterol; 2014 May 07; 20(17):5031-5. PubMed ID: 24833846
    [Abstract] [Full Text] [Related]

  • 8. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
    Marini JC, Sendecki J, Cornillie F, Popp JW, Black S, Blank M, Gils A, Van Stappen T, Hamann D, Rispens T, Thérien L, Chun K, Shankar G.
    AAPS J; 2017 Jan 07; 19(1):161-171. PubMed ID: 27600137
    [Abstract] [Full Text] [Related]

  • 9. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ, Blokzijl T, Festen EAM, Pham BT, Faber KN, Brouwer E, Dijkstra G.
    PLoS One; 2018 Jan 07; 13(12):e0208922. PubMed ID: 30533022
    [Abstract] [Full Text] [Related]

  • 10. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
    Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, Coscas D, Bar-Meir S, Goldstein I, Chowers Y.
    Gut; 2011 Jan 07; 60(1):41-8. PubMed ID: 20519742
    [Abstract] [Full Text] [Related]

  • 11. Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit.
    Dave MB, Dherai AJ, Desai DC, Keny BG, Shetty DN, Kulkarni S, Peddy K, Ashavaid TF.
    Indian J Gastroenterol; 2020 Oct 07; 39(5):426-434. PubMed ID: 33118097
    [Abstract] [Full Text] [Related]

  • 12. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
    Nasser Y, Labetoulle R, Harzallah I, Berger AE, Roblin X, Paul S.
    Dig Dis Sci; 2018 Oct 07; 63(10):2714-2721. PubMed ID: 29948562
    [Abstract] [Full Text] [Related]

  • 13. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
    Van Stappen T, Brouwers E, Tops S, Geukens N, Vermeire S, Declerck PJ, Gils A.
    Ther Drug Monit; 2015 Aug 07; 37(4):479-85. PubMed ID: 25525757
    [Abstract] [Full Text] [Related]

  • 14. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.
    Hernández-Breijo B, Chaparro M, Cano-Martínez D, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiménez I, Barreiro-de Acosta M, Vera I, Martín-Arranz MD, Mesonero F, Sempere L, Gomollón F, Hinojosa J, Gisbert JP, Guijarro LG, PREDICROHN study group from GETECCU.
    Biochem Pharmacol; 2016 Dec 15; 122():33-41. PubMed ID: 27664854
    [Abstract] [Full Text] [Related]

  • 15. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C.
    Inflamm Bowel Dis; 2014 Oct 15; 20(10):1714-21. PubMed ID: 25069030
    [Abstract] [Full Text] [Related]

  • 16. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
    Fréling E, Peyrin-Biroulet L, Poreaux C, Morali A, Waton J, Schmutz JL, Guéant JL, Barbaud A.
    Eur J Gastroenterol Hepatol; 2015 Oct 15; 27(10):1200-8. PubMed ID: 26181108
    [Abstract] [Full Text] [Related]

  • 17. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
    Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S.
    Am J Gastroenterol; 2013 Jun 15; 108(6):962-71. PubMed ID: 23419382
    [Abstract] [Full Text] [Related]

  • 18. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment.
    Rolandsdotter H, Marits P, Sundin U, Wikström AC, Fagerberg UL, Finkel Y, Eberhardson M.
    Int J Mol Sci; 2017 Mar 07; 18(3):. PubMed ID: 28272355
    [Abstract] [Full Text] [Related]

  • 19. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, Haberman Y, Shouval DS, Weintraub I, Eliakim R, Ben-Horin S, Weiss B.
    J Pediatr Gastroenterol Nutr; 2018 Oct 07; 67(4):507-512. PubMed ID: 29901557
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.